SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Momenta Pharmaceuticals Inc.
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
3027 64 0 MNTA
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1827MNTA <i> ReadMeFirst </i> updated for insider shareholdings; anticoaDewDiligence_on_SI-8/17/2008
1826<i>Does anyone have any speculation on what the other follow-on biologics DewDiligence_on_SI-8/9/2008
1825<<<i>Von E is a bring speaker, IMO.</i>> I am certain you LJM-8/6/2008
1824Thanks for the link. Von E is a bring speaker, IMO.DewDiligence_on_SI-8/6/2008
1823Nothing new to report on Amphastar’s ANDA. So says Paul Bisaro on today’s CC.DewDiligence_on_SI-8/6/2008
1822I just listened to this download from the SF Commonwealth Club. Blueprint for CLJM-8/5/2008
1821As of 2Q08, Copaxone was the world’s largest-selling MS drug with a 26% share: DewDiligence_on_SI-8/1/2008
1820<b>2Q08 Lovenox Sales by Region</b> Worldwide, Lovenox sales rose 5DewDiligence_on_SI-7/31/2008
1819Index to Posts on M118 Clinical Trials: siliconinvestor.comDewDiligence_on_SI-7/29/2008
1818Momenta Pharmaceuticals Announces Results From a Phase 1 Study of M118 AdministeLJM-7/29/2008
1817I might reconsider my emotional stance.nigel bates-7/29/2008
1816<i>I'll be really annoyed if they get taken out in the next 12 months.DewDiligence_on_SI-7/28/2008
1815Thanks for that. I'll be really annoyed if they get taken out in the next 1nigel bates-7/28/2008
1814MNTA <i>ReadMeFirst</i> updated for edited transcript of 2Q08 CC andDewDiligence_on_SI-7/28/2008
1813<i>Does this fact give any advantage for M118 over Lovenox?</i> A pDewDiligence_on_SI-7/28/2008
1812>> The lack of a drug interaction was expected, but it’s nonetheless conseIRWIN JAMES FRANKEL-7/28/2008
1811<i>headlines say it's clean with aspirin and clodipogrel.</i> MDewDiligence_on_SI-7/28/2008
1810drug interaction results headline just came through, M118. headlines say it'scaram(o)uche-7/28/2008
1809Edited Transcript from 2Q08 Conference Call: siliconinvestor.comDewDiligence_on_SI-7/28/2008
1808CAMBRIDGE, Mass., Jul 25, 2008 (PrimeNewswire via COMTEX News Network) -- MomenIRWIN JAMES FRANKEL-7/25/2008
1807interesting fund activity and stats that you may be interested in for your Read Ian@SI-7/25/2008
1806MNTA <i>ReadMeFirst</i> updated again… <i>[Several new entrieDewDiligence_on_SI-7/25/2008
1805EMEA Approves Bayer’s Xarelto for VTE Prevention: siliconinvestor.comDewDiligence_on_SI-7/25/2008
1804<i> Hasn't the COM patent on Copaxone expired?</i> Yes, it has.DewDiligence_on_SI-7/24/2008
1803Hasn't the COM patent on Copaxone expired? ijIRWIN JAMES FRANKEL-7/24/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News